title: Inhibition of Non-flux-Controlling Enzymes Deters Cancer Glycolysis by Accumulation of Regulatory Metabolites of Controlling Steps.
abstract: Glycolysis provides precursors for the synthesis of macromolecules and may contribute to the ATP supply required for the constant and accelerated cellular duplication in cancer cells. In consequence, inhibition of glycolysis has been reiteratively considered as an anti-cancer therapeutic option. In previous studies, kinetic modeling of glycolysis in cancer cells allowed the identification of the main steps that control the glycolytic flux: glucose transporter, hexokinase (HK), hexose phosphate isomerase (HPI), and glycogen degradation in human cervix HeLa cancer cells and rat AS-30D ascites hepatocarcinoma. It was also previously experimentally determined that simultaneous inhibition of the non-controlling enzymes lactate dehydrogenase (LDH), pyruvate kinase (PYK), and enolase (ENO) brings about significant decrease in the glycolytic flux of cancer cells and accumulation of intermediate metabolites, mainly fructose-1,6-bisphosphate (Fru1,6BP), and dihydroxyacetone phosphate (DHAP), which are inhibitors of HK and HPI, respectively. Here it was found by kinetic modeling that inhibition of cancer glycolysis can be attained by blocking downstream non flux-controlling steps as long as Fru1,6BP and DHAP, regulatory metabolites of flux-controlling enzymes, are accumulated. Furthermore, experimental results and further modeling showed that oxamate and iodoacetate inhibitions of PYK, ENO, and glyceraldehyde3-phosphate dehydrogenase (GAPDH), but not of LDH and phosphoglycerate kinase, induced accumulation of Fru1,6BP and DHAP in AS-30D hepatoma cells. Indeed, PYK, ENO, and GAPDH exerted the highest control on the Fru1,6BP and DHAP concentrations. The high levels of these metabolites inhibited HK and HPI and led to glycolytic flux inhibition, ATP diminution, and accumulation of toxic methylglyoxal. Hence, the anticancer effects of downstream glycolytic inhibitors are very likely mediated by this mechanism. In parallel, it was also found that uncompetitive inhibition of the flux-controlling steps is a more potent mechanism than competitive and mixed-type inhibition to efficiently perturb cancer glycolysis.
authors.affiliation: Departamento de Bioquímica, Instituto Nacional de Cardiología Mexico City, Mexico.
authors.forename: Álvaro
authors.initials: Á
authors.lastname: Marín-Hernández
authors.affiliation: Departamento de Bioquímica, Instituto Nacional de Cardiología Mexico City, Mexico.
authors.forename: José S
authors.initials: JS
authors.lastname: Rodríguez-Zavala
authors.affiliation: Departamento de Bioquímica, Instituto Nacional de Cardiología Mexico City, Mexico.
authors.forename: Isis
authors.initials: I
authors.lastname: Del Mazo-Monsalvo
authors.affiliation: Departamento de Bioquímica, Instituto Nacional de Cardiología Mexico City, Mexico.
authors.forename: Sara
authors.initials: S
authors.lastname: Rodríguez-Enríquez
authors.affiliation: Departamento de Bioquímica, Instituto Nacional de Cardiología Mexico City, Mexico.
authors.forename: Rafael
authors.initials: R
authors.lastname: Moreno-Sánchez
authors.affiliation: Departamento de Bioquímica, Instituto Nacional de Cardiología Mexico City, Mexico.
authors.forename: Emma
authors.initials: E
authors.lastname: Saavedra
keywords: cancer glycolysis; enolase inhibition; feed-back inhibition; metabolic regulation; oxamate; pyruvate kinase inhibition; uncompetitive inhibition